Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Aeries has turned fiscal 2026 adjusted EBITDA positive and sells an AI-enabled GCC model to private-equity and middle-market clients, but the latest filings also show going-concern doubt, Nasdaq delisting proceedings, FPA obligations and control weaknesses.
OpenAEON is trying to turn ABP-450 into a U.S. therapeutic BOTOX biosimilar, but the current setup combines FDA-pathway optionality with no commercial revenue, going-concern language, a short runway, listing pressure and heavy Daewoong concentration.
OpenAccenture has record Q2 bookings, $5.9 billion of FY2025 generative AI bookings, and elite cash conversion. The decision point is whether AI and managed services can outrun selective consulting demand, U.S. federal pressure, and the cost of reshaping an almost
OpenAECOM has record backlog, rising net service revenue, raised FY2026 earnings guidance, a shareholder-return machine, and a bold AI/advisory margin story. The pressure point is less glamorous: Q2 fiscal 2026 free cash flow was negative because collections and c
OpenAchieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
Open